Given that DARPP-32 is upregulated in gefitinib-resistant NSCLC cells, we designed experiments to assess the functional effects of DARPP-32 overexpression in the presence of EGFR TKI. This evidence concerns the gene PPP1R1B and non-small cell lung carcinoma.